Is denying RAI ablation in the low risk differentiated thyroid cancer patients justified?

被引：0
|
作者：
Agrawal, K. [1 ]
Kashyap, R. [1 ]
Bhattacharya, A. [1 ]
Mittal, B. R. [1 ]
机构：
[1] PGIMER, Chandigarh, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2011年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S223 / S224
页数：2
相关论文
共 50 条
  • [31] Review of thyroid ablation rates with RAI based on I131 uptake in differentiated thyroid carcinoma
    Keys, M.
    Faul, C.
    Boychek, O.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S531 - S531
  • [32] Outcomes of Low-Risk Differentiated Thyroid Cancer (DTC) without Radioactive Iodine (RAI) Ablation Therapy Post-Thyroidectomy: An Experience from a Tertiary Centre in Karachi
    Fatima, Nazish
    Kiran, Zareen
    Iqbal, Javaid
    Baloch, Akhtar Ali
    Habib, S. M. Salman
    Ahmed, Akhtar
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2024, 34 (08): : 968 - 973
  • [33] Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer
    Klain, Michele
    Zampella, Emilia
    Manganelli, Mariarosaria
    Gaudieri, Valeria
    Nappi, Carmela
    D'Antonio, Adriana
    Piscopo, Leandra
    Volpe, Fabio
    Pace, Leonardo
    Schlumberger, Martin
    Cuocolo, Alberto
    ENDOCRINE, 2021, 71 (02) : 378 - 384
  • [34] Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer
    Manganelli, M.
    Klain, M.
    Zampella, E.
    Volpe, F.
    Piscopo, L.
    De Risi, M.
    De Risi, M.
    Gaudieri, V.
    Nappi, C.
    D' Antonio, A.
    Limone, S.
    Pace, L.
    Cuocolo, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S179 - S180
  • [35] Risk of structural persistent disease in pediatric patients with low or intermediate risk differentiated thyroid cancer
    Michele Klain
    Emilia Zampella
    Mariarosaria Manganelli
    Valeria Gaudieri
    Carmela Nappi
    Adriana D’Antonio
    Leandra Piscopo
    Fabio Volpe
    Leonardo Pace
    Martin Schlumberger
    Alberto Cuocolo
    Endocrine, 2021, 71 : 378 - 384
  • [36] FDG plus /RAI plus patients with distant metastases from differentiated thyroid cancer can benefit from RAI treatment
    Males, L.
    Grimaldi, S.
    Terroir, M.
    Lumbroso, J.
    Deandreis, D.
    Berdelou, A.
    Baudin, E.
    Schlumberger, M.
    Leboulleux, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S323 - S323
  • [37] EFFECT OF POST-SURGICAL RAI THERAPY ON PARATHYROID FUNCTION IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
    Zhang, Aimi
    Li, Panli
    Liu, Qiufang
    Peng, Shiyao
    Huang, Gang
    Song, Shaoli
    ENDOCRINE PRACTICE, 2020, 26 (04) : 416 - 422
  • [38] Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
    Lv, Rong-Bin
    Wang, Qing-Gang
    Liu, Chao
    Liu, Fang
    Zhao, Qing
    Han, Jian-Guo
    Ren, Dao-Ling
    Liu, Bin
    Li, Cheng-Li
    ONCOTARGETS AND THERAPY, 2017, 10 : 4051 - 4057
  • [39] Dynamic risk assessment in patients with differentiated thyroid cancer
    Abelleira, Erika
    Jerkovich, Fernando
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2024, 25 (01): : 79 - 93
  • [40] Dynamic risk assessment in patients with differentiated thyroid cancer
    Erika Abelleira
    Fernando Jerkovich
    Reviews in Endocrine and Metabolic Disorders, 2024, 25 : 79 - 93
12345